[go: up one dir, main page]

AR064212A1 - Uso de profarmacos de analogos de gaba para tratar enfermedades - Google Patents

Uso de profarmacos de analogos de gaba para tratar enfermedades

Info

Publication number
AR064212A1
AR064212A1 ARP070105514A ARP070105514A AR064212A1 AR 064212 A1 AR064212 A1 AR 064212A1 AR P070105514 A ARP070105514 A AR P070105514A AR P070105514 A ARP070105514 A AR P070105514A AR 064212 A1 AR064212 A1 AR 064212A1
Authority
AR
Argentina
Prior art keywords
substituted
cycloheteroalkyl
cycloalkyl
heteroalkyl
arylalkyl
Prior art date
Application number
ARP070105514A
Other languages
English (en)
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of AR064212A1 publication Critical patent/AR064212A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para usar profármacos de análogos de GABA y sus composiciones farmacéuticas para tratar migrana, fibromialgia, esclerosis lateral amiotrofica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica, y composiciones farmacéuticas de profármacos de análogos de GABA de utilidad para tratar migrana, fibromialgia, esclerosis lateral amiotrofica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica. Reivindicacion 1: Un método para tratar una enfermedad elegida de migrana, fibromialgia, esclerosis lateral amiotrofica, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica en un paciente, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad terapéuticamente efectiva de al menos un compuesto elegido de la formula (1), la formula (2), la formula (3), la formula (4), una sal farmacéuticamente aceptable de cualquiera de los anteriores, un solvato farmacéuticamente aceptable de cualquiera de los anteriores, y un N oxido farmacéuticamente aceptable de cualquiera de los anteriores, en donde: R1 es elegido de hidrogeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido; R2 y R3 son elegidos independientemente de hidrogeno, alquilo, alquilo sustituido, alcoxicarbonilo, alcoxicarbonilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, carbamoilo, sustituido carbamoílo, cicloalquilo, cicloalquilo sustituido, heteroalquilo, heteroalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido, o R2 y R3 junto con el átomo de carbono al que están unidos forman un anillo elegido de anillo cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, y cicloheteroalquilo sustituido; y R4 es elegido de acilo, acilo sustituido, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido.
ARP070105514A 2006-12-08 2007-12-10 Uso de profarmacos de analogos de gaba para tratar enfermedades AR064212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87356106P 2006-12-08 2006-12-08

Publications (1)

Publication Number Publication Date
AR064212A1 true AR064212A1 (es) 2009-03-18

Family

ID=39186816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105514A AR064212A1 (es) 2006-12-08 2007-12-10 Uso de profarmacos de analogos de gaba para tratar enfermedades

Country Status (13)

Country Link
US (2) US20080161393A1 (es)
EP (1) EP2101752A1 (es)
JP (1) JP2010512314A (es)
CN (1) CN101652133A (es)
AR (1) AR064212A1 (es)
AU (1) AU2007332904A1 (es)
BR (1) BRPI0720252A2 (es)
CA (1) CA2672044A1 (es)
EA (1) EA200970487A1 (es)
MX (1) MX2009006080A (es)
PE (1) PE20081389A1 (es)
TW (1) TW200845959A (es)
WO (1) WO2008073257A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2005025562A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
PL1677767T3 (pl) * 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2365574T3 (es) * 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
CA2740087C (en) 2008-10-08 2019-07-23 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
JP2012519212A (ja) * 2009-03-03 2012-08-23 ゼノポート，インコーポレイティド Ｒ−バクロフェンプロドラッグの持効性放出経口投与形
EP2521453B1 (en) * 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
US20130261165A1 (en) * 2010-12-16 2013-10-03 The Mclean Hospital Corporation Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
JP2015529254A (ja) * 2012-09-21 2015-10-05 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法
HK1219268A1 (zh) 2013-02-26 2017-03-31 Xenoport, Inc. 1-(酰氧基)-烷基氨基甲酸酯化合物的制造方法
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
CN107271599A (zh) * 2016-04-08 2017-10-20 上海市刑事科学技术研究院 一种人唾液中地西泮及其代谢物的在线spe lc-ms/ms分析方法
WO2019090001A1 (en) * 2017-11-02 2019-05-09 California Institute Of Technology Neurokinin antagonists and uses thereof
CN114621119A (zh) * 2018-05-14 2022-06-14 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
DE112019007341B4 (de) * 2019-06-20 2024-06-13 Hitachi High-Tech Corporation Substanzanalysator und substanzanalyseverfahren
RU2709527C1 (ru) * 2019-07-29 2019-12-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Met-Glu-His-Phe-Pro-Gly-Pro (семакса) для коррекции дисбиоза при хроническом иммобилизационном стрессе
US12147601B1 (en) 2022-04-28 2024-11-19 Snap Inc. Removing eye blinks from EMG speech signals
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
KR100512506B1 (ko) * 1996-03-14 2005-12-21 워너-램버트 캄파니 엘엘씨 제약제제로서신규한치환시클릭아미노산
IL125364A0 (en) * 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6680343B1 (en) * 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
CA2333024C (en) * 1998-07-09 2002-03-26 Warner-Lambert Company Method for the treatment of insomnia
US6490454B1 (en) * 1998-08-07 2002-12-03 Telefonaktiebolaget Lm Ericsson (Publ) Downlink observed time difference measurements
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20040002543A1 (en) * 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PL368452A1 (en) * 2001-11-08 2005-03-21 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
EP1469841A1 (en) * 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
WO2003080588A1 (en) * 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
AU2003297927A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004089289A2 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
WO2005019163A2 (en) * 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005025562A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
CN1871021B (zh) * 2003-09-17 2010-07-28 什诺波特有限公司 用gaba类似物的前药治疗或预防多动腿综合征
MXPA06003396A (es) * 2003-09-25 2006-06-08 Warner Lambert Co Profarmacos de aminoacidos con afinidad por la proteina a 2d.
PL1677767T3 (pl) * 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
WO2006050514A1 (en) * 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US20060192353A1 (en) * 2005-02-08 2006-08-31 Schubert Peter J Method of producing a rollover arming signal based on off-axis acceleration
US20070049627A1 (en) * 2005-08-23 2007-03-01 Tran Pierre V Treating vulvodynia using prodrugs of GABA analogs
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2008060572A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
WO2009094577A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use

Also Published As

Publication number Publication date
US20080161393A1 (en) 2008-07-03
EA200970487A1 (ru) 2009-12-30
CA2672044A1 (en) 2008-06-19
AU2007332904A1 (en) 2008-06-19
JP2010512314A (ja) 2010-04-22
WO2008073257A1 (en) 2008-06-19
PE20081389A1 (es) 2008-11-19
BRPI0720252A2 (pt) 2014-01-07
US20120041061A1 (en) 2012-02-16
MX2009006080A (es) 2009-07-14
TW200845959A (en) 2008-12-01
EP2101752A1 (en) 2009-09-23
CN101652133A (zh) 2010-02-17

Similar Documents

Publication Publication Date Title
AR064212A1 (es) Uso de profarmacos de analogos de gaba para tratar enfermedades
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
UA101328C2 (uk) Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met
TW200740760A (en) Malonamide derivatives
MEP43308A (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
CL2008002330A1 (es) Compuestos derivados de alcoholes de 1-fenil-2-piridinilalquilo, inhibidores de la fosfodiesterasa 4 (pde4); proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; y su uso para preparar medicamentos utiles en la prevencion o tratamiento de asma, bronquitis cronica y epoc.
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
MX2009004289A (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
BRPI0510365A (pt) composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
MX2010006209A (es) Derivados de quinoxalinilo.
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
MX2009009384A (es) Malonamidas como antagonistas de orexina.
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina

Legal Events

Date Code Title Description
FB Suspension of granting procedure